Data catalogue

 

The aim of this catalogue is to make it easier to find data published by the EMCDDA. Currently, the list only contains a fraction of all data published by the agency over the years but we are adding to it all the time as part of our commitment to open data. Note that the aim of this catalogue is not necessarily to provide the data itself (though it may do so in some cases) but mainly to allow you to find the data.

Title Publication date Data series Keywords
EU drug Market: MDMA: source data #EUDrugMarkets, drug law offences, drug markets, MDMA/ecstasy, potency/purity, prevalence and patterns of drug use, price, supply of drugs
Drugs in municipal wastewater in Europe: source data (2025) wastewater amphetamine, cannabis, cocaine, ketamine, MDMA/ecstasy, methamphetamine, prevalence and patterns of drug use, wastewater analysis
IPA data sheets background tables and source data
European Web Survey on Drugs (EWSD) 2024: top-level findings and methodological information — source data European Web Survey on Drugs (EWSD) European Web Survey on Drugs (EWSD), prevalence and patterns of drug use, web-based surveys, amphetamine, benzodiazepines, cannabis, cocaine, GHB, heroin, ketamine, kratom, MDMA/ecstasy, methamphetamine, NPS, synthetic cannabinoids, synthetic cathinones
Source data for European Drug Emergencies Network (Euro-DEN Plus) data explorer Euro-DEN Plus amphetamine, benzodiazepines, cocaine, Euro-DEN, GHB, heroin, hospital emergencies, methamphetamine, NPS, overdose
Data tables: impact of economic recessions on the use of illicit drugs economics, prevalence and patterns of drug use
Frequently asked questions (FAQ) 2024: drug overdose deaths in Europe: source data drug-related deaths, harm reduction, overdose, preventing overdoses, toxicology
Source data for the Viral hepatitis elimination barometer among people who inject drugs in Europe hepatitis B virus (HBV), hepatitis C virus (HCV), injecting drug use
Source data for EU Drug Market: EU Drug Market: New psychoactive substances — In-depth analysis #EUDrugMarkets, drug markets, opioids, production of drugs, seizures of drugs, supply of drugs, benzodiazepines, early warning system, HHC, ketamine, NPS, synthetic cannabinoids, synthetic cathinones
Statistical Bulletin 2024 — syringe residues (ESCAPE) ESCAPE amphetamine, cocaine, ESCAPE (syringe residues), Euro-DEN, heroin, injecting drug use, ketamine, MDMA/ecstasy, opioids
Statistical Bulletin 2024 — hospital emergencies data (Euro-DEN plus) Euro-DEN Plus amphetamine, cocaine, Euro-DEN, heroin, hospital emergencies, ketamine, MDMA/ecstasy, opioids, overdose
Statistical Bulletin 2024 — drug checking data from the TEDI network TEDI drug checking amphetamine, cocaine, drug-checking, ketamine, MDMA/ecstasy
Statistical Bulletin 2024 — health and social responses HSR health and social responses, OAT (opioid agonist treatment), treatment provision
Statistical Bulletin 2024 — drug law offences DLO criminal justice system, drug law offences, drug markets, law
Statistical Bulletin 2024 — drug use and prison DUP amphetamine, cannabis, cocaine, heroin, MDMA/ecstasy, methamphetamine, prevalence and patterns of drug use, prison
Statistical Bulletin 2024 — price, purity and potency PPP amphetamine, cannabis, cocaine, drug markets, heroin, LSD, MDMA/ecstasy, methamphetamine, potency/purity, price, supply of drugs, supply reduction
Statistical Bulletin 2024 — seizures of drugs SZR amphetamine, cannabis, cocaine, drug markets, LSD, MDMA/ecstasy, methamphetamine, seizures of drugs, supply of drugs, supply reduction, trafficking
Statistical Bulletin 2024 — treatment demand data TDI cannabis, cocaine, Gender and drugs, heroin, key indicators, methamphetamine, TDI (key indicator), treatment of drug use
Statistical Bulletin 2024 — problem drug use PDU Gender and drugs, injecting drug use, key indicators, problem drug use
Statistical Bulletin 2024 — drug-related infectious diseases DRID DRID (key indicator), drug-related infectious diseases, hepatitis B virus (HBV), HIV, key indicators
Statistical Bulletin 2024— drug-induced deaths DRD DRD (key indicator), drug-related deaths, Gender and drugs, health harms of drug use, key indicators, overdose
Statistical Bulletin 2024 – prevalence and patterns of drug use in the general population GPS alcohol, amphetamine, cannabis, cocaine, Gender and drugs, general population surveys (GPS), key indicators, LSD, MDMA/ecstasy, prevalence and patterns of drug use, tobacco, young people
European Drug Report 2024: Trends and Developments: source data #EDR24, amphetamine, benzodiazepines, cannabis, cocaine, drug consumption facility, drug law offences, drug markets, drug situation, drug-checking, drug-related deaths, drug-related infectious diseases, ESCAPE (syringe residues), Euro-DEN, health and social responses, health harms of drug use, heroin, ketamine, LSD, methamphetamine, needle and syringe provision, NPS, OAT (opioid agonist treatment), opioids, policy, potency/purity, prevalence and patterns of drug use, price, seizures of drugs, supply of drugs, synthetic cannabinoids, synthetic cathinones, trafficking, treatment of drug use, wastewater analysis
Drug checking data from the Trans European Drugs Information (TEDI) network: source data TEDI drug checking amphetamine, cocaine, drug-checking, ketamine, MDMA/ecstasy, methamphetamine
Drugs in municipal wastewater in Europe: source data wastewater amphetamine, cannabis, cocaine, ketamine, MDMA/ecstasy, methamphetamine, prevalence and patterns of drug use, wastewater analysis

What is included in this catalogue?

The catalogue includes:

  • The Statistical Bulletin which is mainly based on data submitted to the agency by the Reitox network of national focal points for the main reporting countries (27 EU Member States plus Türkiye and Norway) on a yearly basis and which forms the basis for the EMCDDA's annual overview of the drug situation in Europe, as well as other key outputs. These data are generally at the national level. The topics covered by these data sets include general population surveys, drug-related deaths, drug-related infectious diseases, treatment demand, markets and seizures data, etc. Only the most recent Statistical Bulletins are currently included.
  • Data from ongoing collaborations with networks or partner organisations, These data sets are usually at the city-level and are considered complementary sources to the main reported data sets. Examples include data from SCORE (wastewater), TEDI (drug.checking), Euro-DEN (hospital emergencies), ESCAPE (syringe residues), etc.
  • Data from studies or specific projects. These data sets are usually once-off and may be the result of primary research or based on aggregation of other existing data sets, or some combination of both. These data in the past have not been published in 'raw format' but are often included in PDFs or only made available as graphics, etc. Data from non-reporting countries (e.g. countries in the EU neighbourhood) are often published in this format,
  • Data which has been manipulated, combined, or further processed for the purposes of analysis, data visualisation or similar. This is almost always done when included as part of a publication or output and usually referred to as the 'source data'.
  • Data about the EMCDDA or activities e.g. accounts, expenditure or other data about the agency.
Top